Findings from our current study further corroborated previous reports that in the setting of hyperlipidemia, statins treatment not only could improve dyslipidemia, but also concomitantly decreased Rho kinase activity which consequently reduced CRP level and enhanced NO production[8,21]. Here, CRP is linked to hyperlipidemia.